List of Excipients in Branded Drug LUPRON DEPOT

Lupron Depot Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Lupron Depot is a long-acting leuprolide acetate product built around biodegradable polymeric microspheres. Its commercial value comes from sustained release, multiple dosing intervals, established clinical use, and a delivery platform that is difficult to reproduce consistently at scale. The main excipient opportunity is not a new inactive ingredient by itself. It is the development of improved depot polymers, reconstitution systems, injection devices, and alternative long-acting formulations that reduce handling burden and injection-site complications.

What is Lupron Depot and how does its depot formulation work?

Lupron Depot contains leuprolide acetate, a gonadotropin-releasing hormone agonist, in biodegradable microspheres. The microspheres are suspended before intramuscular injection and gradually release leuprolide as the polymer matrix hydrates and degrades.

The product is marketed in several dosing intervals:

Product	Leuprolide acetate dose	Dosing interval	Principal uses
Lupron Depot	3.75 mg	1 month	Endometriosis, uterine fibroids
Lupron Depot	11.25 mg	3 months	Endometriosis, uterine fibroids
Lupron Depot	30 mg	4 months	Endometriosis
Lupron Depot	45 mg	6 months	Endometriosis
Lupron Depot-PED	7.5 mg	1 month	Central precocious puberty
Lupron Depot-PED	11.25 mg	3 months	Central precocious puberty
Lupron Depot-PED	30 mg	6 months	Central precocious puberty

The FDA labeling identifies a biodegradable copolymer of lactic and glycolic acids as the core release-controlling excipient. The formulation also uses excipients associated with microsphere manufacture and reconstitution, including mannitol, gelatin, carboxymethylcellulose sodium, polysorbate 80, and water for injection, depending on the product component and presentation.[1]

The formulation strategy has four functional layers:

1. Leuprolide acetate provides the pharmacologic activity.
2. A lactide-glycolide copolymer controls release over one to six months.
3. Stabilizers and bulking agents support microsphere formation and product handling.
4. A diluent system enables reconstitution immediately before injection.

What excipients protect the commercial performance of Lupron Depot?

The most important excipient is the biodegradable poly(lactic-co-glycolic acid), commonly called PLGA. PLGA is not a passive filler. Its molecular weight, lactide-to-glycolide ratio, end-group chemistry, particle size, porosity, residual solvent profile, and degradation behavior can materially affect clinical performance.

PLGA microspheres

PLGA controls:

• Initial burst release
• Duration of drug exposure
• Microsphere integrity
• Acidic microenvironment formation during polymer degradation
• Residual drug content
• Injection suspension behavior
• Lot-to-lot release reproducibility

The lactide-to-glycolide ratio is commercially important. Higher glycolide content generally increases water uptake and degradation rate, while higher lactide content tends to slow degradation because lactide is more hydrophobic. The commercial formulation must balance release duration with acceptable local tolerability and manufacturing yield.

Longer-acting Lupron Depot presentations require more than simply increasing the drug load. They require control over polymer degradation, particle morphology, drug distribution, syringeability, and the pharmacokinetic transition between dose intervals.

Mannitol

Mannitol can act as a bulking agent and contribute to powder structure and reconstitution behavior. In a microsphere product, its role can affect cake or powder characteristics, suspension concentration, and the physical handling of the vial or syringe components.

Gelatin

Gelatin may support microsphere processing or formulation structure. Its presence creates supply-chain and regulatory considerations, including source control, animal-origin documentation, transmissible spongiform encephalopathy controls, and patient or market preferences regarding animal-derived materials.

A commercial opportunity exists for gelatin-free formulations using synthetic polymers, recombinant proteins, or alternative stabilizer systems. Such a change would require comparative assessment of particle formation, release kinetics, stability, and local tolerability.

Carboxymethylcellulose sodium

Carboxymethylcellulose sodium is used in the diluent system as a suspending or viscosity-modifying agent. The concentration must support uniform suspension without making the product difficult to inject through the intended needle.

Polysorbate 80

Polysorbate 80 can improve wetting and dispersion during reconstitution. Its use creates familiar biologic and injectable-product concerns, including oxidation, hydrolysis, peroxide formation, and interaction with packaging or drug substance impurities.

A polysorbate-free or low-polysorbate reconstitution system could be commercially attractive if it improves stability without reducing dose uniformity or increasing injection force.

What formulation patents protect Lupron Depot?

The commercial protection for Lupron Depot has historically depended on a combination of drug patents, sustained-release composition patents, manufacturing know-how, dosing patents, and regulatory exclusivity. The core leuprolide molecule is long off patent. The relevant technical barriers are the depot formulation and its manufacturing process.

Patent categories relevant to Lupron Depot

Patent category	Protected subject matter	Commercial relevance
Drug substance	Leuprolide acetate and related analogs	Largely historical for Lupron Depot
Polymer composition	PLGA composition, polymer properties, drug loading	Controls release and product performance
Microsphere manufacture	Emulsification, solvent removal, drying, particle sizing	Creates process-reproduction barriers
Dosage interval	Monthly, quarterly, four-month, or six-month administration	Supports product line extensions
Reconstitution	Diluent composition, suspension stability, injection performance	Protects user experience and administration
Device presentation	Dual-chamber syringe, vial, transfer system	Reduces preparation steps and dosing errors
Method of use	Endometriosis, fibroids, precocious puberty, oncology	Can support regulatory and commercial segmentation
Quality attributes	Release profile, residual solvents, particle-size distribution	Often protected through know-how and specifications

Public patent records and FDA Orange Book records should be separated. A patent may cover a formulation or method but not be listed in the Orange Book. Conversely, an Orange Book listing may affect an abbreviated new drug application challenge without covering every commercial feature of the product.

The central strategic point is that a competitor can face a meaningful development barrier even after basic composition patents expire. Demonstrating pharmaceutical equivalence for a complex injectable depot can require substantial analytical, manufacturing, and clinical work.

What is the Orange Book status and generic-entry risk for Lupron Depot?

Lupron Depot is associated with NDA 019010, while Lupron Depot-PED is separately regulated within the Lupron product family. The FDA Orange Book remains the controlling source for current listed patents, certifications, and regulatory exclusivity status.[2]

The market risk is different from conventional oral generics. A leuprolide depot competitor must generally address:

• Microsphere composition
• Particle-size distribution
• Drug-release profile
• Reconstitution characteristics
• Injection-site tolerability
• Dose proportionality across strengths
• Stability and sterility
• Manufacturing consistency
• Clinical or comparative pharmacokinetic requirements

A Paragraph IV challenge could target listed patents covering a depot formulation, dosing regimen, or manufacturing process. The economic effect would depend on the patent expiration date, litigation outcome, settlement terms, and whether the challenger receives a first-filer advantage.

For business planning, the Lupron Depot market should be divided into three risk categories:

Risk category	Likely effect
Core drug-substance patents expired	Low barrier to active ingredient entry
Depot composition or process patents expired or weak	Moderate technical competition
Complex injectable equivalence and manufacturing constraints	High practical barrier despite limited patent protection

Lupron Depot therefore has a lower theoretical patent barrier than a recently launched protected product but a higher execution barrier than a conventional tablet.

When did Lupron Depot lose exclusivity?

The original leuprolide acetate patent estate is historical, and the product has been marketed for decades. The relevant commercial exclusivity today is product-specific rather than molecule-specific.

FDA approval history shows that Lupron Depot entered the market through multiple supplemental approvals and new presentations, including pediatric and extended-interval formulations.[1] Those approvals created separate clinical, manufacturing, and regulatory positions even when they relied on the same active ingredient.

The principal loss-of-exclusivity issue is not whether leuprolide is generic. It is whether a competing company can launch a therapeutically substitutable long-acting injectable with sufficient product quality and regulatory support.

Potential launch paths include:

1. An ANDA referencing Lupron Depot.
2. A 505(b)(2) application using a modified depot, dose, device, or administration system.
3. A completely separate NDA for a new leuprolide delivery technology.
4. A competing GnRH agonist or antagonist with a different pharmacology.
5. A biosimilar-style strategy, which does not apply because leuprolide is a synthetic peptide drug rather than a biologic.

Are biosimilar risks relevant to Lupron Depot?

No. Lupron Depot is not a biologic and does not face biosimilar substitution under the Public Health Service Act. The relevant competitors are generic injectables, 505(b)(2) products, and alternative branded hormonal therapies.

The technical risk is closer to complex generic competition than biosimilar competition. A competitor must reproduce or clinically bridge a controlled-release injectable system, rather than demonstrate biosimilarity to a protein biologic.

Which companies challenge or compete with Lupron Depot?

The most relevant competitive set includes other leuprolide products and alternative androgen-deprivation or gonadal-suppression therapies.

Eligard

Eligard contains leuprolide acetate but uses the ATRIGEL delivery system, a polymeric in situ gel that forms a depot after injection. It is marketed by Tolmar Pharmaceuticals and is primarily used for advanced prostate cancer.[3]

Eligard demonstrates that the same active ingredient can support a separate commercial platform through excipient and delivery-system differentiation. Its polymer technology changes the reconstitution and injection process compared with Lupron Depot microspheres.

Fensolvi

Fensolvi is a six-month leuprolide acetate product for central precocious puberty. It uses a different long-acting delivery system and is marketed by Tolmar.[4] Its commercial position demonstrates the value of reducing pediatric injection frequency, even when the active ingredient is already established.

Leuprolide acetate generics

Generic and authorized-generic leuprolide products may compete in selected presentations. Substitution depends on FDA-approved product equivalence, payer policy, state substitution rules, inventory, and physician preference. Depot injectables may experience slower substitution than oral products because clinics control procurement and administration.

Alternative hormonal products

Competing therapies include:

• Histrelin implants
• Goserelin implants
• Triptorelin injections
• Degarelix injections
• Relugolix oral therapy
• Elagolix and relugolix combinations for gynecologic indications

These products compete on dosing frequency, onset of hormonal suppression, flare management, administration setting, adverse-event profile, and total treatment cost.

What commercial opportunities exist in Lupron Depot excipients?

The strongest opportunities are platform improvements that support regulatory differentiation or manufacturing economics.

1. Improved PLGA systems

Excipient suppliers can develop PLGA grades optimized for:

• Six-month release
• Lower initial burst
• Reduced acidic degradation products
• Better peptide stabilization
• More predictable particle-size distribution
• Lower residual solvent levels
• Higher encapsulation efficiency

A polymer grade with stronger batch consistency can reduce manufacturing waste and shorten scale-up timelines. The commercial model could involve custom polymer supply, formulation licensing, or co-development with a 505(b)(2) sponsor.

2. Alternative biodegradable polymers

Potential alternatives include polycaprolactone, polyanhydrides, polyorthoesters, and hybrid polymer systems. Their value depends on release control and injectability. Replacing PLGA is difficult because the alternative must maintain sterility, degradation control, drug stability, and acceptable tissue response.

3. Ready-to-use presentations

A ready-to-use or simplified reconstitution product could reduce nursing time and preparation errors. Commercially relevant improvements include:

• Pre-filled dual-chamber syringes
• Closed-transfer reconstitution systems
• Lower injection force
• Reduced needle clogging
• Longer in-use stability after reconstitution
• Clearer dose confirmation
• Reduced product waste

The device and diluent system can support a 505(b)(2) strategy even where the active ingredient is generic.

4. Excipient systems for peptide stabilization

Leuprolide is a synthetic peptide and can be affected by hydrolysis, oxidation, aggregation, adsorption, and polymer-associated degradation. Commercial opportunities include stabilizer systems that preserve potency during microsphere manufacture and storage.

Candidate technologies include amino-acid stabilizers, sugar-based protectants, surfactant alternatives, antioxidant systems, and polymer surface modifications. Each candidate must be assessed against injectable safety, extractables and leachables, sterilization, and release testing.

5. Pediatric administration

The pediatric market has a strong incentive to reduce injection burden. Formulations with less painful administration, smaller injection volume, longer duration, and simpler preparation can command commercial value even without a new active ingredient.

The regulatory opportunity is strongest where the formulation provides a clinically meaningful administration improvement and can support a new indication, device claim, or dosage presentation.

How strong is the Lupron Depot patent estate?

The estate is strongest in technical know-how and manufacturing complexity, not in the underlying leuprolide molecule.

Estate element	Relative strength
Leuprolide active ingredient	Low, because of age and prior art
PLGA depot concept	Moderate to low for broad claims
Specific microsphere parameters	Moderate where narrowly claimed and reproducible
Six-month release formulations	Moderate, depending on claim scope
Manufacturing process	Moderate to strong as practical know-how
Reconstitution system	Moderate
Device integration	Moderate
Indication patents	Variable and generally narrower
Regulatory exclusivity	Product- and approval-specific

Narrow formulation claims can still matter if they cover the commercial product and are difficult to design around. Broad claims to biodegradable microspheres or PLGA alone face substantial prior-art exposure.

Process know-how may have greater value than published patents. Critical parameters can include emulsion conditions, solvent removal rates, drying cycles, polymer molecular-weight distribution, drug loading, residual moisture, and release testing methods.

What patent litigation and settlement risks affect Lupron Depot?

Potential disputes would likely involve four issues:

1. Whether a generic depot is therapeutically equivalent.
2. Whether the generic infringes a listed formulation or method patent.
3. Whether a 505(b)(2) product requires additional clinical evidence.
4. Whether a settlement delays launch or grants an authorized-generic arrangement.

A settlement could include a license, an agreed launch date, supply rights, a manufacturing relationship, or restrictions on specific strengths. For an established product, the commercial significance of a settlement depends on whether the challenger enters the high-volume monthly presentation or a smaller extended-interval segment.

No broad biosimilar settlement framework applies. The principal legal framework is the Hatch-Waxman pathway for ANDAs and conventional patent litigation under the Drug Price Competition and Patent Term Restoration Act.[5]

How does Lupron Depot compare with Eligard and Fensolvi?

Attribute	Lupron Depot	Eligard	Fensolvi
Active ingredient	Leuprolide acetate	Leuprolide acetate	Leuprolide acetate
Delivery technology	Biodegradable microspheres	ATRIGEL in situ gel	Long-acting polymeric depot
Main market	Gynecology, pediatric endocrinology	Prostate cancer	Pediatric endocrinology
Dosing range	1 to 6 months	1 to 6 months, by presentation	6 months
Excipient strategy	PLGA microsphere and diluent system	Polymer gel and solvent system	Extended-release pediatric depot
Differentiation	Established product family and indications	Oncology positioning and delivery platform	Six-month pediatric dosing
Main commercial risk	Generic depot competition	Alternative androgen-deprivation therapies	Pediatric long-acting competitors

Lupron Depot has the broadest historical product family. Eligard provides the clearest example of delivery-system differentiation. Fensolvi shows how an extended dosing interval can support a separate product position in a targeted population.

What manufacturing and geographic barriers affect commercial entry?

Manufacturing barriers include sterile microsphere production, controlled particle sizing, solvent removal, aseptic filling, polymer qualification, and validated release testing. The facility must manage both drug-product sterility and complex physical performance specifications.

Geographic barriers include:

• Different approved strengths by jurisdiction
• Country-specific pediatric indications
• Local patent and supplementary protection certificate terms
• Reimbursement policies
• Import requirements for animal-derived excipients
• Local substitution rules for injectable products
• Procurement concentration in hospitals and specialty clinics

A supplier with a qualified PLGA platform and sterile injectable manufacturing capability can support multiple regional products. A supplier that only provides commodity mannitol, polysorbate, or carboxymethylcellulose is less differentiated.

Key Takeaways

• Lupron Depot's core formulation strategy is a biodegradable PLGA microsphere system for one- to six-month leuprolide release.
• PLGA properties, microsphere morphology, release kinetics, and reconstitution performance are the highest-value excipient variables.
• The active ingredient is commercially mature; the principal entry barriers are complex injectable development, manufacturing reproducibility, and regulatory comparability.
• The strongest commercial opportunities involve improved polymers, lower-burst formulations, ready-to-use delivery systems, pediatric administration, and excipient substitutions.
• Eligard and Fensolvi demonstrate that leuprolide products can be differentiated through delivery technology and dosing interval.
• Lupron Depot is exposed to generic and 505(b)(2) competition, not biosimilar competition.
• The patent estate is more defensible through narrow formulation claims and manufacturing know-how than through broad claims to leuprolide or PLGA.
• FDA Orange Book listings, patent certifications, and any Paragraph IV litigation should be evaluated by NDA, strength, and presentation rather than at the brand level.

FAQs

Can a new excipient create a standalone Lupron Depot competitor?

Yes. A new polymer, stabilizer, or diluent can support a 505(b)(2) product if it creates a clinically or administratively meaningful difference and is supported by appropriate chemistry, manufacturing, pharmacokinetic, safety, and regulatory data.

Is PLGA the only viable polymer for a leuprolide depot?

No. Other biodegradable polymers may be technically viable, but they must match PLGA's release control, biocompatibility, sterilization profile, injectability, and manufacturing reproducibility.

What is the highest-value excipient improvement for Lupron Depot?

A polymer or polymer-processing system that reduces initial burst release while maintaining a predictable six-month exposure profile would have high commercial value. A second high-value opportunity is a ready-to-use presentation that reduces reconstitution time and injection errors.

Could a gelatin-free Lupron Depot formulation improve market access?

Yes. A gelatin-free formulation could simplify animal-origin controls and address market preferences in jurisdictions or institutions that restrict animal-derived materials. The formulation would still need to match stability, release, and administration performance.

Which Lupron product has the strongest formulation differentiation?

Eligard has clear delivery-system differentiation through ATRIGEL, while Lupron Depot has the broader historical product family and indication footprint. Fensolvi has strong dosing-interval differentiation in central precocious puberty.

References

1. U.S. Food and Drug Administration. (2024). Lupron Depot and Lupron Depot-PED prescribing information. AbbVie Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. U.S. Food and Drug Administration. (2024). Eligard prescribing information. Tolmar Pharmaceuticals, Inc. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024). Fensolvi prescribing information. Tolmar Pharmaceuticals, Inc. https://www.accessdata.fda.gov
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417. https://www.congress.gov/bill/98th-congress/house-bill/3605